Clinical Trials Browser

cemiplimab × Other solid neoplasm × Clear all

NCT06651593 2026-02-17

Phase II Biomarker Study of SAR444881 in Combination With Cemiplimab in Solid Tumors

Phase 2 Recruiting

Other solid neoplasm

Solid Tumors

NCT07234058 2026-02-11

LAG-MAPS

Phase 2 Not yet recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT04626635 2026-02-02

COMBINE-EGFR-1

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06302426 2026-01-16

Trial of INI-4001 in Patients With Advanced Solid Tumours

Phase 1 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT03192345 2024-08-07

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors

Phase 1 Completed

Other solid neoplasm

Malignant Solid Tumor

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Phase 2 Unknown

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma